The University of Windsor, in partnership with Shogun Maitake Canada, has unveiled groundbreaking findings that could redefine natural approaches to cancer care across North America. The research, recently highlighted by the university and the company, centres on Odaira Black Maitake Extract (OBME)—a highly concentrated, Health Canada-certified mushroom extract that shows striking anticancer activity.

Dose- and Time-Dependent Cancer Cell Death

Led by Dr. Siyaram Pandey, head of the University of Windsor’s Department of Chemistry and Biochemistry, graduate researchers demonstrated that OBME triggers cancer cell apoptosis—the programmed death of cancerous cells—in a dose- and time-dependent manner. Their in-vitro studies confirmed that higher concentrations and longer treatment durations of OBME markedly reduce cancer cell growth and increase cell death.

In addition to direct cancer cell impact, the team’s data indicate that OBME enhances immune system activity, slows tumour progression, and can augment the effectiveness of conventional chemotherapies. When used alongside standard cancer treatments, OBME may lower toxicity and improve overall quality of life, offering a valuable complement to existing protocols.

Next Phase: Integrating Immunotherapy

The University of Windsor researchers, collaborating with Shogun Maitake Canada, are preparing the next stage of investigation: testing OBME in combination with immunotherapy. This research aims to evaluate whether pairing OBME with advanced immune-based therapies can deliver even stronger clinical outcomes for patients facing various cancers.

A Canadian Hub for High-Quality Maitake Production

Shogun Maitake has operated a state-of-the-art production centre in London, Ontario since 2016, ensuring organic, pesticide-free cultivation of Black Maitake mushrooms. The company’s proprietary methods, perfected by CEO and President Yoshinobu Odaira over four decades, consistently produce mushrooms with superior β-glucan (beta-glucan) content—a key compound linked to immune and anticancer benefits.

Due to the mushroom’s delicate nature, maintaining purity and potency is notoriously challenging. Shogun Maitake’s controlled environment ensures consistent quality that meets or exceeds the standards found in Japan, long known as a global leader in medicinal mushroom production.

From Research to Accessible Supplements

Building on these laboratory results, Shogun Maitake Canada has introduced Shogun Maitake EX, a clinically supported supplement delivering the optimal dosage of OBME. Alongside Prothera, another OBME-based formulation, these products are designed to be taken individually or as a combination care package. Both are registered with Natural Product Numbers (NPNs) from Health Canada—Prothera (NPN: 80115706) and EX (NPN: 80118634)—ensuring regulatory compliance and consumer confidence.

In a mission-led initiative to mark the University of Windsor’s breakthrough, Shogun Maitake will donate 2,000 bottles of its OBME supplements to individuals across North America undergoing cancer treatment. Beginning August 15, 2025, eligible participants can apply at shogunmaitake.com to receive a one-month supply.

Expert Perspective

“These findings offer an incredible opportunity to ease suffering, make chemotherapy more effective, and give cancer patients the immune support to fight back,” said Yoshinobu Odaira. “I have dedicated my life to refining cultivation methods for Black Maitake mushrooms and advancing research that unlocks their full potential in the global fight against cancer.”

A Natural Pathway in Modern Oncology

The University of Windsor–Shogun Maitake collaboration highlights Canada’s growing role in evidence-based natural health innovation. By marrying academic rigour with advanced cultivation technology, the project paves the way for integrative oncology strategies that support patients’ immune systems and reduce treatment side effects.

Health practitioners, natural health retailers, and consumers can follow ongoing developments in OBME research and product availability at shogunmaitake.com. This Canadian-led innovation underscores how functional mushrooms are emerging as powerful allies in next-generation cancer care.

The Synergy Company, a pioneer in certified organic nutritional and herbal supplements, has appointed Jennifer Briggs as Chief Executive Officer (CEO) to lead the brand into its next phase of growth. Briggs, widely recognised for her expertise in purpose-driven leadership and operational excellence, will guide the company’s mission to combine innovation, sustainability, and community values with uncompromising product quality.

Building on a Three-Decade Legacy

Founded in 1992 by Mitchell May, The Synergy Company has become a respected global name in organic supplements, celebrated for its vertical integration, in-house manufacturing, and cutting-edge ingredient sourcing. For over 30 years, its unwavering commitment to purity, scientific formulation, and social and environmental responsibility has earned widespread recognition, including a Nutrition Business Journal Management Achievement Award for leadership and performance.

May, who remains founder and chairman, expressed strong confidence in the appointment: “Jennifer’s leadership and dedication to values-driven business practices embody the culture and future of The Synergy Company. She will help ensure our independence while expanding our innovation and sustainability commitments for generations to come.”

A Proven Leader in Purpose-Driven Growth

Briggs brings more than two decades of executive experience across consumer packaged goods, food and beverage, and employee-ownership advocacy. She spent 12 years on the executive team at New Belgium Brewing, played key leadership roles as CEO of Modern Times Brewing and CXO of Karl Strauss Brewing, and has held governance positions in construction and technology.

Her commitment to shared prosperity is reflected in her role as Board Chair of the National Center for Employee Ownership and as an Executive Fellow at Rutgers University’s Institute for the Study of Employee Ownership and Profit Sharing. Briggs also holds a master’s degree in organisational leadership and was named Brewbound Person of the Year in 2022. Her achievements and thought leadership have been featured in Fabulous California, Fabulous People, and Brewer Magazine.

Advancing Innovation and Sustainability

As CEO, Briggs aims to expand The Synergy Company’s portfolio of certified organic nutritional supplements and herbal formulas, strengthening its position in the natural health marketplace. Her focus will include:

• Enhancing product innovation to meet rising global demand for clean, science-backed supplements.
• Expanding sustainable ingredient sourcing that protects ecosystems and supports fair trade.
• Maintaining rigorous in-house manufacturing standards, ensuring potency, purity, and traceability.

“I’m inspired by The Synergy Company’s legacy of uncompromising quality and its vision for holistic wellness,” said Briggs. “We will continue to honour Mitchell and Jayne May’s founding ideals while exploring new opportunities to connect people with natural, effective solutions for lifelong health.”

Deep Roots in Moab, Utah

Despite its international reach, The Synergy Company remains deeply tied to its Moab, Utah community, where it provides meaningful career opportunities and supports local sustainability initiatives. This connection to place is central to its identity and reflects its belief that good business is inseparable from social and planetary responsibility.

Why This Leadership Change Matters for Natural Health Retailers

Briggs’s appointment signals continued stability and forward momentum for natural product retailers and health food stores that carry The Synergy Company’s line of supplements. With consumer demand for certified organic, sustainably sourced vitamins and herbal products stronger than ever, retailers can expect ongoing investment in product development, supply chain transparency, and consumer education—key factors for long-term category growth.

Setting a New Standard in Skincare and Nutraceutical Innovation

When it comes to vitamin C, both the skincare and natural health supplement industries have long wrestled with the same challenge: stability. L-ascorbic acid, the purest form of vitamin C, is notoriously unstable. Once exposed to water, oxygen, or light, it oxidizes quickly—losing potency and efficacy before consumers can finish the product.

On September 9, 2025, Los Angeles–based skincare company Matter of Fact announced it had been granted U.S. Patent No. 12,390,444 for a breakthrough method that finally solves this decades-old problem. The patent covers a novel way of solubilizing and stabilizing vitamin C in a water-free formulation, ensuring potency and clinical performance from the first day of use to the very end of its two-year shelf life.

This development does not only mark a milestone for the beauty sector—it also carries important implications for supplement formulators, health retailers, and the broader nutraceutical industry.

Why Vitamin C Stability Matters

Vitamin C remains one of the world’s most in-demand ingredients. In skincare, it is prized for its ability to brighten the complexion, reduce the appearance of wrinkles, and defend against oxidative stress caused by UV exposure and pollution. In supplements, it supports immune health, collagen production, and antioxidant protection.

The challenge has always been that L-ascorbic acid degrades rapidly in water, the main solvent in most creams, serums, and ingestible products. Many formulas either sacrifice stability for performance or use derivatives of vitamin C that are less potent than the pure form.

Matter of Fact’s approach changes the game. By using urea as a co-solvent and combining it with ferulic acid in a proprietary water-free solubilization process, the company has created a system that keeps vitamin C fully dissolved, highly stable, and clinically effective.

Clinical Evidence and Industry Validation

The patented process is not just theoretical. Matter of Fact conducted three independent 12-week clinical studies on 64 participants, even testing products near the end of their two-year shelf life. The results demonstrated:

• Noticeable improvement in dark spot intensity.
• Significant reduction in the appearance of fine lines and forehead wrinkles.
• Proven efficacy that matches—or exceeds—the leading global benchmarks for vitamin C serums.

The research was peer-reviewed and published in the Journal of Investigative Dermatology (2023) and presented at the International Societies for Investigative Dermatology (ISID) conference in Tokyo. This was the first time an independent skincare brand had presented at the prestigious event, further highlighting the innovation’s credibility.

Founder-Led Innovation

Unlike many patents developed by contract research organizations, this one was personally spearheaded by Paul Baek, Matter of Fact’s founder and a Harvard-educated, first-generation Korean-American. Baek began working on vitamin C stabilization in 2018, determined to overcome one of the industry’s longest-standing formulation barriers.

“We didn’t just aim to stabilize vitamin C,” Baek explained. “We set out to redefine what’s possible and reshape industry standards. This patent proves that independent brands can bring meaningful innovations to market and create real change.”

Implications for the Supplement and Natural Health Sector

While this patent applies specifically to skincare, the implications reach into the nutraceutical industry. Canadian natural health retailers and formulators should take note:

• Extended Shelf Stability: Consumers often hesitate to purchase high-dose vitamin C serums or supplements for fear they will lose potency before finishing the product. Improved stability could lead to higher consumer trust and repeat sales.
• Clean Label Expectations: Today’s wellness consumers want fewer additives and maximum efficacy. Stabilization technologies that avoid heavy preservatives or artificial stabilizers are likely to resonate with this market.
• Innovation Opportunities: Independent Canadian supplement companies can look to Matter of Fact’s patent as a model for pushing boundaries. As Health Canada tightens regulatory expectations for natural health products, demonstrating both stability and efficacy will become critical.

According to Market Data Forecast, the global vitamin C market is projected to grow at a CAGR of 5.2% through 2030, driven by demand in both functional skincare and dietary supplements. Stabilization breakthroughs like this could accelerate that growth by building consumer confidence in long-term product performance.

A Turning Point in the Vitamin C Story

Matter of Fact’s achievement is more than just another patent—it represents a shift in how brands approach ingredient integrity and consumer trust. By ensuring vitamin C maintains its potency for two full years, the company has effectively rewritten the rules of one of the supplement and skincare industry’s most important categories.

For Canadian retailers, health practitioners, and product formulators, this innovation is a reminder that the next wave of growth lies in science-backed, clinically proven solutions. As consumers demand both transparency and results, the brands that invest in research—not just marketing—will set the standard for the years ahead.

Doseology Sciences Inc. has entered into an asset purchase and sale agreement to acquire the Feed That Brain™ (FTB) division from Joseph Mimran & Associates Inc. for a total consideration of $400,000, structured through the issuance of company securities. The acquisition includes FTB’s full suite of assets, including intellectual property, distribution agreements, and branding rights.

Founded by Forbes-recognized wellness innovator Rena R. Dempsey, FTB specializes in cognitive performance and “beauty-from-within” supplements. This acquisition positions Doseology to accelerate the Canadian rollout of its clean energy pouches, reinforcing its strategy to lead in wellness-driven performance and nicotine harm reduction formats.

In conjunction with the acquisition, Doseology has appointed retail visionary Joseph Mimran as a strategic advisor under a three-year agreement. Mimran, known for building and revitalizing brands such as Kit and Ace, Tilley, and Mastermind Toys, will provide high-level guidance on brand development, retail strategy, and growth execution.

“Doseology is building something both innovative and timely,” said Mimran. “I’m excited to work alongside the team in shaping a brand that redefines how energy and performance can be delivered.”

The transaction remains subject to regulatory approval and customary closing conditions.

Designed with a clinically researched blend of adaptogens, herbs, and minerals, AGZ supports the body’s natural rhythm across three key phases of rest: winding down, deep sleep, and waking refreshed.

Unlike traditional sleep aids, AGZ is a melatonin-free formula, leveraging research-backed ingredients including Magtein® magnesium L-threonate, saffron, L-theanine, ashwagandha, valerian, and lemon balm. These components have been clinically shown to reduce stress, calm the nervous system, and promote restorative sleep cycles without dependency.

AG1 CEO Kat Cole explained that the move into sleep support is a direct response to customer demand and emerging science. “In addition to the growing research on the impact sleep has on overall health, thousands of customer conversations over the years made it clear that foundational nutrition was just the beginning of our opportunity, and sleep issues were a huge need we could address,” said Cole. “With the launch of AGZ, our second all-new product, we continue supporting customers’ health journeys, now both morning and night.”

AGZ complements AG1’s original daily formula by establishing a full-circle wellness routine — AG1 fuels energy and focus throughout the day, while AGZ enhances nightly rest and recovery. The product is NSF Certified for Sport®, ensuring rigorous safety and quality standards. It contains no added sugars, artificial colours, flavours, or binders, making it suitable for a broad consumer base, including elite athletes and health-conscious professionals.

Designed for nightly use, AGZ comes in a convenient powdered format, formulated to mix with as little as four ounces of liquid. Available in three flavours — Mixed Berry, Chocolate, and Chocolate Mint — AGZ is free of artificial sweeteners and crafted to integrate seamlessly into consumers’ evening rituals.

Since its founding in 2010, AG1 has built a global following among wellness enthusiasts, health professionals, and athletes. Following recent product innovations like AG1 Next Gen and AG1 Flavours, as well as expanded retail distribution through Costco, the launch of AGZ underscores AG1’s commitment to offering holistic solutions that support whole-body health around the clock.

The gut–brain connection is no longer fringe—your customers already know the language, and many walk in asking for specific psychobiotic strains or barrier-support nutrients by name. The challenge for seasoned health retailers isn’t whether to stock the category, but how to structure, position, and turn it into a repeatable revenue driver without slipping into overclaim territory.

Over the past five years, “intestinal permeability” has shifted from an obscure research term into a consumer keyword, even if they still call it “leaky gut.” Food sensitivities, low-grade inflammation, and mood dysregulation are increasingly framed as a connected cluster. For the trade, that means a category play that straddles digestion, mood, and functional nutrition—and demands a merchandising approach that reflects both the science and the psychology of the buyer.

Product Architecture and Merchandising Strategy

Psychobiotic probiotics remain the anchor SKU. The combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 continues to lead in published data for stress modulation and mild anxiety, making them the strain profile to highlight. The difference between moving units and letting them gather dust often comes down to whether you call out the strain codes in signage. With a category-savvy consumer, label literacy is a trust trigger. Make it impossible for them to miss those codes on the shelf.

Prebiotics—especially galacto-oligosaccharides (GOS)—are the logical upsell and cross-sell. Position them as a functional companion that feeds the right bacteria for gut–mood outcomes. Stock GOS in clean powders or sachets, not buried in blends where the dose disappears into a proprietary label. Merchandising GOS adjacent to psychobiotics in a two-product bundle has shown a consistent lift in basket size for stores that trialled the set.

Barrier-support nutrients like glutamine and zinc-carnosine are your third tier. They’re not as sexy in marketing, but they’re indispensable for the customer already deep into gut repair protocols. For them, you don’t need to explain “why glutamine”—you need to ensure the SKU you carry is clinically relevant in dose and format. Low-excipient powders and capsule options let you cater to both high-compliance and high-convenience shoppers.

Display strategy is where seasoned retailers separate themselves. A “Gut–Mood Connection” endcap is the most efficient footprint for the category, but the layout matters. Place your psychobiotics top-shelf and at eye level. Prebiotics should sit directly below, ideally in a clean, single-brand or single-format block for visual authority. Anchor with barrier-support nutrients at the base, where the most committed customer will still look. Keep the entire section merchandised with vertical brand blocking, not scattered by category—shoppers follow the solution, not the supplier.

Education, Timing, and Messaging for Repeat Business

In this category, the customer segment you’re attracting is already self-educated, so in-store materials should go deeper than “supports gut health.” They want timelines, synergies, and specific nutrient forms. A laminated quick-reference for staff—listing SKUs, strain codes, active doses, and typical use protocols—turns every floor interaction into a high-value conversation.

The seasonality of this category is worth noting. September and January remain the two highest-conversion windows for gut–mood products, aligning with stress transitions and “reset” mindsets. Tying bundle promotions to these periods, with a modest discount on the full three-part protocol, will push trial while maintaining margin.

Messaging needs to be precise. Your audience has already read the blogs, watched the webinars, and compared products online. They’re not coming to you for the headline—they’re coming to validate their choice. That means stripping fluff and replacing it with the differentiators that matter: strain specificity, clinically relevant dosing, clean formulations, and synergistic combinations.

Executed well, this is not a small adjunct to digestion or mood support—it’s a standalone destination category with the potential for high repeat purchase rates, strong average order values, and deep brand loyalty. In an increasingly competitive retail landscape, building authority in gut–mood merchandising is as much about operational discipline as it is about product knowledge. The customers are already primed. Your job is to make the choice obvious, the results consistent, and the return visit inevitable.

The gut–mood category has evolved from an emerging health trend into a retail powerhouse. Today’s shoppers are walking into stores already asking for specific probiotic strains, targeted prebiotic fibres and barrier-support nutrients by name. This is not about teaching the basics—it’s about mastering the merchandising strategy that meets their expectations, reinforces your authority and keeps them coming back.

In our latest IHR Magazine feature, we explore how to build a three-tier product mix that anchors with psychobiotics, layers in functional prebiotics and finishes with barrier-support nutrients in clinically relevant formats. We look at how to design an endcap that guides the shopper’s journey and keeps the focus on the solution rather than the supplier. We show why precise, clinically literate messaging is essential for validating customer choices and positioning your store as the most credible source in the market. And we explain how to capitalize on seasonal peaks like September and January with bundled promotions that not only boost trial but also protect margins.

Gut–mood products are no longer just a subcategory of digestion—they have become a destination category with some of the highest average order values, loyalty potential and year-round relevance in natural health retail. The only real question is not if you should own this space, but how well you will execute it.

Athletic performance setbacks are often attributed to training intensity, injury, or suboptimal conditioning, but less frequently to early metabolic dysfunction. A recent case from Dr. Anjanaa Subramanian, MD (Natural Medicine), CFMP, MPT, PGDHM, demonstrates why clinicians working with young athletes should also investigate subtle biochemical imbalances and dietary insufficiencies that may impair performance long before overt disease manifests.

The Case:
A 16-year-old competitive swimmer presented with central adiposity, elevated body fat (32% by DEXA), slow post-exercise recovery, and persistent brain fog. Despite rigorous training and adherence to a high-protein diet, she was experiencing reduced athletic performance and mental focus.

Functional testing revealed a fasting insulin of 11 μIU/mL, indicative of early insulin resistance—a finding that can be easily missed in lean adolescents, especially those with athletic physiques. Her dietary profile was skewed toward animal protein with limited phytonutrient and fibre intake, a factor that, combined with high training load, may have contributed to metabolic inflexibility, adrenal strain, and low-grade inflammation.

The Intervention:
Dr. Subramanian implemented a multi-pronged functional medicine protocol, anchored by a personalized herbal adaptogenic blend including Withania somnifera (ashwagandha), Bacopa monnieri (brahmi), Tinospora cordifolia (guduchi), Glycyrrhiza glabra (licorice), Rubia cordifolia (manjistha), and Asparagus racemosus (shatavari). These botanicals were selected for their synergistic effects on cortisol modulation, mitochondrial support, neuroinflammation reduction, and insulin sensitivity.

Nutritional adjustments focused on increasing fibre, plant diversity, and phytonutrient density through seasonal vegetables, legumes, soaked seeds, and fermented foods. Low-glycaemic fruits were added to support antioxidant intake without spiking blood sugar. A regimen of breathwork and yoga complemented the plan, targeting autonomic balance and recovery optimization.

The Outcome:
After 12 weeks, the patient’s fasting insulin dropped to 6 μIU/mL. Visceral fat decreased to 25%, cognitive clarity improved, and post-training recovery times shortened. Importantly, the swimmer reported renewed confidence and stamina in competition settings.

Why It Matters:
This case underscores the importance of evaluating metabolic, neuroendocrine, and gut–immune function in adolescent athletes presenting with unexplained fat gain, plateaued performance, and recovery challenges. Even in the absence of overt disease, functional medicine interventions—particularly when incorporating targeted herbal therapeutics—can recalibrate metabolism and restore peak performance potential.

Clinical Takeaway:

• Early insulin resistance can occur in lean, high-performing athletes.
• Poor dietary diversity and fibre insufficiency may contribute to metabolic inflexibility.
• Herbal adaptogens and plant-forward nutrition can deliver measurable improvements in insulin sensitivity, fat distribution, and cognitive performance.

Dr. Subramanian’s integrative approach bridges the gap between modern diagnostics and time-tested botanicals, offering a model for sports practitioners seeking to address under-recognised drivers of performance decline in youth athletics.